Baqsimi (glucagon)
- Region
- 🇪🇺 EU
- Active substance
- glucagon
- Company
- Amphastar France Pharmaceuticals
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 17 Oct 2019
- EU approval
- Mon 16 Dec 2019
- Application
- EMEA/H/C/003848
- ATC
- H04AA01
- Official record
- www.ema.europa.eu
Indication
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zegalogue Authorised · Zealand Pharma A/S
- 🇪🇺 Ogluo Authorised · Strongbridge Dublin Limited
Follow Baqsimi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.